Trial reportLeukemia2020
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.
Abstract readClinical Trial, Phase IIIComparative StudyLetter
In one paragraph
Trial report in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.Cancer reports (Hoboken, N.J.) · 2024Pooled it
- Arsenic trioxideHaematologica · 2025Trial
- An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).Blood cancer journal · 2022Trial
- Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy.Blood advances · 2021Trial
- Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).Proceedings of the National Academy of Sciences of the United States of America · 2021Trial
- Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.Leukemia · 2026Article
- Establishment and validation of a 28-day clinical outcome prediction model for acute promyelocytic leukemia based on an early platelet-coagulation factor combined transfusion strategy.American journal of cancer research · 2026Article
- Cancer Reversion Therapy: Prospects, Progress and Future Directions.Current issues in molecular biology · 2025Review
- MALNC: a new mutant NPM1/IDH2Cancer gene therapy · 2025Article
- Patients with high-risk acute promyelocytic leukemia need maintenance therapy for 1 year - the PROS.Haematologica · 2025Article
- Long-term Persistence of Dysplastic Features in Patients with Acute Promyelocytic Leukemia Treated with All-trans Retinoic Acid and Arsenic Trioxide.Mediterranean journal of hematology and infectious diseases · 2025Article
- Influence of white blood cell count trajectories on the risk of differentiation syndrome during induction therapy with all-trans-retinoic acid and arsenic trioxide in pediatric acute promyelocytic leukemia.Frontiers in pediatrics · 2025Article
- Therapy-related myeloid neoplasms following curative treatment of acute promyelocytic leukemia: incidence, correlation with therapeutic regimen, and future directions.Journal of hematopathology · 2024Article
- The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression.Biomedicines · 2024Review
- Review
- The Promise of Retinoids in the Treatment of Cancer: Neither Burnt Out Nor Fading Away.Cancers · 2023Review
- Combination Effect of Deferoxamine and Arsenic Trioxide on Viability and Vitality of APL Like Cell Line.Ethiopian journal of health sciences · 2023Article
- The characteristics and long-term outcomes of acute promyelocytic leukemia patients with early intracranial hemorrhage.International journal of hematology · 2023Article
- Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death.Cell death & disease · 2023Article
- At What Point Are Long-Term (>5 Years) Survivors of APL Safe? A Study from the SEER Database.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors.
Laura Cicconi *Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Uwe Platzbecker *Universitätsklinikum Leipzig, Leipzig, Germany.
Giuseppe AvvisatiEmatologia e Trapianto di cellule staminali, Università Campus Bio-Medico, Rome, Italy.
Francesca PaoloniGIMEMA Data Center, Rome, Italy.
Christian ThiedeUniversitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden, Germany.
Marco VignettiGIMEMA Data Center, Rome, Italy.
Paola FaziGIMEMA Data Center, Rome, Italy.
Felicetto FerraraDipartimento di Ematologia e Trapianto di Cellule Staminali, Ospedale Cardarelli, Napoli, Italy.
Mariadomenica DivonaLaboratorio di Oncoematologia, Policlinico Tor Vergata, Rome, Italy.
Francesco AlbanoDipartimento di Ematologia, Università di Bari, Bari, Italy.ORCID http://orcid.org/0000-0001-7926-6052
Fabio EfficaceGIMEMA Data Center, Rome, Italy.
Marco SborgiaU.O. di Ematologia Clinica, Pescara, Italy.
Eros Di BonaDipartimento di Terapie cellulari ed Ematologia, Unità Operativa di Ematologia, Ospedale S. Bortolo, Vicenza, Italy.
Massimo BrecciaDipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy.
Erika BorlenghiDipartimento di Ematologia, Spedali Civili, Brescia, Italy.ORCID http://orcid.org/0000-0002-4666-3817
Roberto CairoliGrande Ospedale Metropolitano Niguarda, SC Ematologia, Milan, Italy.
Alessandro RambaldiAzienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.ORCID http://orcid.org/0000-0002-3739-7502
Lorella MelilloCasa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.
Giorgio La NasaCentro Trapianti Midollo Osseo, Ospedale R. Binaghi, Università di Cagliari, Cagliari, Italy.
Walter FiedlerUniversity Hospital Hamburg-Eppendorf, Hamburg, Germany.
Peter BrossartDepartment of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, CIO Bonn, Bonn, Germany.
Bernd HertensteinKlinikum Bremen Mitte, Bremen, Germany.
Helmut R SalihUniversity Hospital Tubingen, Tubingen, Germany.
Ombretta AnnibaliEmatologia e Trapianto di cellule staminali, Università Campus Bio-Medico, Rome, Italy.
Mohammed WattadKliniken Essen Süd, Essen, Germany.
Michael LubbertUniversity Medical Center, Freiburg, Germany.
Christian H BrandtsGoethe University Frankfurt, Frankfurt, Germany.
Mathias HanelKlinikum Chemnitz gGmbH, Chemnitz, Germany.
Christoph RolligUniversitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden, Germany.
Norbert SchmitzAsklepios Klinik St Georg Hamburg, Hamburg, Germany.
Hartmut LinkKlinik für Innere Medizin I, Westpfalz-Klinikum, Kaiserslautern, Germany.
Chiara FrairiaCittà della Salute e della Scienza, Hematology, Torino, Italy.
Claudio FozzaUniversity of Sassari, Sassari, Italy.
Alfonso Maria D'ArcoU.O. Medicina Interna e Onco-Ematologica P.O. Umberto I, Nocera Inferiore, Nocera Inferiore, Italy.
Nicola Di RenzoOspedale Vito Fazzi, Lecce, Italy.
Agostino CortelezziFoundation Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.
Francesco FabbianoDivisione di Ematologia e Unità di Trapianti di Midollo Osseo, Ospedale Riuniti Villa Sofia-Cervello, Palermo, Italy.
Konstanze DohnerUniversity Hospital Ulm, Ulm, Germany.
Arnold GanserHannover Medical School, Hannover, Germany.
Hartmut DohnerUniversity Hospital Ulm, Ulm, Germany.
Sergio AmadoriGIMEMA Data Center, Rome, Italy.
Franco MandelliGIMEMA Data Center, Rome, Italy.
Maria Teresa VosoDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy. voso@med.uniroma2.it.ORCID http://orcid.org/0000-0002-6164-4761
Gerhard EhningerUniversitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden, Germany.
Richard F SchlenkNCT Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Francesco Lo-CocoDepartment of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideFemaleFollow-Up StudiesGermanyHumansItalyLeukemia, Promyelocytic, AcuteMaleMiddle AgedProspective StudiesTreatment OutcomeTretinoinArsenic TrioxideTretinoin
Identifiers
PMID
31611624What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.